In part three of Pharmaceutical Executive’s interview with Susan Thomas, LucyRx’s chief commercial officer, Thomas focuses on how new evidence on the cardiometabolic benefits of GLP-1s is reshaping employer-coverage decisions. The interview also explores why the long-term value of preventing serious health events may not be reflected in near-term healthcare spending.
Thomas also points out that employers may find it challenging to look beyond short-term costs but notes that if they do, they can help plans better support higher-risk populations and improve long-term health outcomes by looking to the future.
Share